Company / EPS (Diluted)
Jade Biosciences, Inc. EPS (Diluted) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.44
FY2024
5-year range
-$2.87 / -$1.87
FY2021-FY2024
Trend
+15.0%
vs FY2023
Sector context
#139 of 203
Health Care
What the data says
At $-2.44, Jade Biosciences, Inc.'s eps (diluted) ranks #139 of 203 in the Health Care sector. EPS (Diluted) returned to growth in FY2024 after 2 years of decline, reaching $-2.44.
Based on SEC 10-K filings.
-2.44 in FY2024.
Declined from $-2.10 to $-2.44 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#139 of 203 in Health CareTop 68% of 203This company -$2.44 Sector average -$0.45
▼
-444.0% below sector average
Key checks
Key Insights
- In FY2024, eps (diluted) increased 15.0% year-over-year.
- Ranks #139 out of 203 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.44 | +15.0% |
| FY2023 | -$2.87 | -36.7% |
| FY2022 | -$2.10 | -12.3% |
| FY2021 | -$1.87 | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026